Jagadeesh, Karthik A. http://orcid.org/0000-0002-0957-812X
Dey, Kushal K. http://orcid.org/0000-0002-3520-2345
Montoro, Daniel T.
Mohan, Rahul
Gazal, Steven http://orcid.org/0000-0003-4510-5730
Engreitz, Jesse M. http://orcid.org/0000-0002-5754-1719
Xavier, Ramnik J. http://orcid.org/0000-0002-5630-5167
Price, Alkes L. http://orcid.org/0000-0002-2971-7975
Regev, Aviv http://orcid.org/0000-0003-3293-3158
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (HG009379, MH101244, F32)
Howard Hughes Medical Institute (HHMI)
Article History
Received: 17 May 2021
Accepted: 18 August 2022
First Online: 29 September 2022
Competing interests
: A.R. is a co-founder and equity holder of Celsius Therapeutics and an equity holder in Immunitas and was an SAB member of Thermo Fisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov. From 1 August 2020, A.R. has been an employee of Genentech. The remaining authors declare no competing interests.
Free to read: This content has been made available to all.